180 related articles for article (PubMed ID: 23595697)
1. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
2. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
5. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.
Shen LY; Wang H; Dong B; Yan WP; Lin Y; Shi Q; Chen KN
Oncotarget; 2016 Jan; 7(4):4531-41. PubMed ID: 26673820
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
7. The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Hsiao SM; Chen MW; Chen CA; Chien MH; Hua KT; Hsiao M; Kuo ML; Wei LH
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1556-65. PubMed ID: 25613390
[TBL] [Abstract][Full Text] [Related]
8. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
9. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Fukuda T; Oda K; Wada-Hiraike O; Sone K; Inaba K; Ikeda Y; Miyasaka A; Kashiyama T; Tanikawa M; Arimoto T; Kuramoto H; Yano T; Kawana K; Osuga Y; Fujii T
Gynecol Oncol; 2015 Jun; 137(3):538-45. PubMed ID: 25842161
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
12. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
13. APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types regardless of p53 or MMR status.
Scott BJ; Qutob S; Liu QY; Ng CE
Int J Cancer; 2009 Sep; 125(5):1193-204. PubMed ID: 19444912
[TBL] [Abstract][Full Text] [Related]
14. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
[TBL] [Abstract][Full Text] [Related]
15. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Tai SK; Yang MH; Chang SY; Chang YC; Li WY; Tsai TL; Wang YF; Chu PY; Hsieh SL
Cancer Sci; 2011 Apr; 102(4):895-902. PubMed ID: 21219537
[TBL] [Abstract][Full Text] [Related]
16. Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
Huh WK; Cibull M; Gallion HH; Gan CM; Richard S; Cohn DE
Int J Gynecol Cancer; 2011 Apr; 21(3):494-9. PubMed ID: 21430456
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
18. Therapeutically blocking Interleukin-11 Receptor-α enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours.
Winship A; Van Sinderen M; Rainczuk K; Dimitriadis E
Oncotarget; 2017 Apr; 8(14):22716-22729. PubMed ID: 28186993
[TBL] [Abstract][Full Text] [Related]
19. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.
Thigpen T; Vance RB; Khansur T
Semin Oncol; 1995 Oct; 22(5 Suppl 12):67-75. PubMed ID: 7481864
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
